Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs

PartnershipABO2203Positive

AI Analysis

Summary

Abogen announced a licensing and option agreement with Novartis for worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager, along with exclusive options for other RNA programs leveraging Abogen's proprietary platform.

Outcome Details

Licensing and option agreement for mRNA-encoded T-cell engager (ABO2203) and exclusive options for other RNA programs

Importance:7/10

Sentiment:

0.70

mRNAT-cell engagerlicensing agreementoncologyRNA platform

Related Companies

$NVS

Read the original article

Published by PR Newswire Biotech on October 2, 2026 4:42 AM

Read Original